The first-in-human phase 1 study (NCT01287546) evaluated emibetuzumab monotherapy versus emibetuzumab plus erlotinib (an EGFR TKI) in patients with advanced cancer (NSCLC specifically: n = 4 versus 14, respectively) [45]. Here, EGFR is linked to cancer.